AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (45)

Latest Posts

About This Stock More About This Stock
18 Drugs To Lose Patents In 2017; Could Jeopardize $26.5B For Big Pharma
Article By: Lorimer Wilson
Saturday, April 22, 2017 8:24 PM EDT
With 18 branded drugs on the line, patent losses this year could jeopardize $26.5 billion in annual sales from Big Pharma, projected to be the biggest fall-off until at least 2025.
In this article: AZN, BMY, GSK, LLY, MRK, PFE, SNY, RHHBY, TEVA
Read
Pharma Stock Roundup: Merck Gets CRL For Label Expansion Effort, Roche Cancer Drug Tops
Article By: Arpita Dutt
Friday, April 14, 2017 12:00 PM EDT
It was a relatively slow week with key highlights including a complete response letter (CRL) for Merck’s label expansion efforts for its diabetes drugs and positive data on Roche’s lung cancer treatment.
In this article: AZN, JNJ, MRK, MYL, RHHBY, PFE, BMY
Read
9 Blockbuster Drugs Making Their Debut In 2017; Total Revenue Expected To Be $16B By 2021
Article By: Lorimer Wilson
Tuesday, April 11, 2017 11:56 PM EDT
It is always interesting to see what analysts believe the big new drugs of the year are going to be worth 5 years down the road and Clarivate Analytics has listed the 9 blockbusters their analysts expect to see approved by the FDA this year.
In this article: AZN, LLY, MRK, NVO, NVS, PFE, SNY, RHHBY, INCY, REGN, KITE, TSRO
Read
FDA Nixes Merck’s Request To Have Januvia Cardio Safety Data On Its Label
Article By: Lorimer Wilson
Friday, April 7, 2017 12:10 PM EDT
Merck wanted to state on the label of their diabetes drug Januvia that patients could take it without raising their risk for cardio complications to distinguish themselves from same-class rivals like Onglyza, which has risks. FDA has nixed the idea.
In this article: AZN, MRK
Read
Week In Review: Beijing's Creat Offers $1.3 Billion For Biotest Of Germany
Article By: ChinaBio® Today
Saturday, April 1, 2017 12:27 PM EDT
Creat Group, a Beijing investment firm, has bid to acquire German blood plasma products maker Biotest for $1.3 billion (including debt).
In this article: AZN, JD
Read

PARTNER HEADLINES

Latest Tweets for $AZN

No tweets yet!